6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Diabetic retinopathy as the leading cause of blindness and early predictor of cascading complications—risks and mitigation

      review-article
      1 , 2 , , 3 , , 4 , 4 , 5 , 1 , 2 , 1 , 2 , 6 , 7 , 7 , 8 , 9 , 1 , 2
      The EPMA Journal
      Springer International Publishing
      Predictive, preventive, and personalised medicine (3P/PPPM), Diabetes mellitus, Comorbidities, Diabetic complications, Retinopathy, Proliferative diabetic retinopathy, Blindness, Global burden, Health-to-disease transition, Primary and secondary prevention, Domino effect, Cerebral small vessel disease, Stress, ROS, Ischemic stroke, Mitochondrial injury, Cell death, Metabolic and signalling shifts, Inflammation, Neovascularisation, Analytical tools, Tear fluid, Molecular patterns, Biomarkers, Health policy

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Proliferative diabetic retinopathy (PDR) the sequel of diabetic retinopathy (DR), a frequent complication of diabetes mellitus (DM), is the leading cause of blindness in the working-age population. The current screening process for the DR risk is not sufficiently effective such that often the disease is undetected until irreversible damage occurs. Diabetes-associated small vessel disease and neuroretinal changes create a vicious cycle resulting in the conversion of DR into PDR with characteristic ocular attributes including excessive mitochondrial and retinal cell damage, chronic inflammation, neovascularisation, and reduced visual field. PDR is considered an independent predictor of other severe diabetic complications such as ischemic stroke. A “domino effect” is highly characteristic for the cascading DM complications in which DR is an early indicator of impaired molecular and visual signaling. Mitochondrial health control is clinically relevant in DR management, and multi-omic tear fluid analysis can be instrumental for DR prognosis and PDR prediction. Altered metabolic pathways and bioenergetics, microvascular deficits and small vessel disease, chronic inflammation, and excessive tissue remodelling are in focus of this article as evidence-based targets for a predictive approach to develop diagnosis and treatment algorithms tailored to the individual for a cost-effective early prevention by implementing the paradigm shift from reactive medicine to predictive, preventive, and personalized medicine (PPPM) in primary and secondary DR care management.

          Related collections

          Most cited references152

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Epidemiology of Type 2 Diabetes – Global Burden of Disease and Forecasted Trends

          The rising burden of type 2 diabetes is a major concern in healthcare worldwide. This research aimed to analyze the global epidemiology of type 2 diabetes. We analyzed the incidence, prevalence, and burden of suffering of diabetes mellitus based on epidemiological data from the Global Burden of Disease (GBD) current dataset from the Institute of Health Metrics, Seattle. Global and regional trends from 1990 to 2017 of type 2 diabetes for all ages were compiled. Forecast estimates were obtained using the SPSS Time Series Modeler. In 2017, approximately 462 million individuals were affected by type 2 diabetes corresponding to 6.28% of the world’s population (4.4% of those aged 15–49 years, 15% of those aged 50–69, and 22% of those aged 70+), or a prevalence rate of 6059 cases per 100,000. Over 1 million deaths per year can be attributed to diabetes alone, making it the ninth leading cause of mortality. The burden of diabetes mellitus is rising globally, and at a much faster rate in developed regions, such as Western Europe. The gender distribution is equal, and the incidence peaks at around 55 years of age. Global prevalence of type 2 diabetes is projected to increase to 7079 individuals per 100,000 by 2030, reflecting a continued rise across all regions of the world. There are concerning trends of rising prevalence in lower-income countries. Urgent public health and clinical preventive measures are warranted.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Stroke in China: advances and challenges in epidemiology, prevention, and management

            With over 2 million new cases annually, stroke is associated with the highest disability-adjusted life-years lost of any disease in China. The burden is expected to increase further as a result of population ageing, an ongoing high prevalence of risk factors (eg, hypertension), and inadequate management. Despite improved access to overall health services, the availability of specialist stroke care is variable across the country, and especially uneven in rural areas. In-hospital outcomes have improved because of a greater availability of reperfusion therapies and supportive care, but adherence to secondary prevention strategies and long-term care are inadequate. Thrombolysis and stroke units are accepted as standards of care across the world, including in China, but bleeding-risk concerns and organisational challenges hamper widespread adoption of this care in China. Despite little supporting evidence, Chinese herbal products and neuroprotective drugs are widely used, and the increased availability of neuroimaging techniques also results in overdiagnosis and overtreatment of so-called silent stroke. Future efforts should focus on providing more balanced availability of specialised stroke services across the country, enhancing evidence-based practice, and encouraging greater translational research to improve outcome of patients with stroke.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025

              Diabetes mellitus is a leading cause of mortality and reduced life expectancy. We aim to estimate the burden of diabetes by type, year, regions, and socioeconomic status in 195 countries and territories over the past 28 years, which provide information to achieve the goal of World Health Organization Global Action Plan for the Prevention and Control of Noncommunicable Diseases in 2025. Data were obtained from the Global Burden of Disease Study 2017. Overall, the global burden of diabetes had increased significantly since 1990. Both the trend and magnitude of diabetes related diseases burden varied substantially across regions and countries. In 2017, global incidence, prevalence, death, and disability-adjusted life-years (DALYs) associated with diabetes were 22.9 million, 476.0 million, 1.37 million, and 67.9 million, with a projection to 26.6 million, 570.9 million, 1.59 million, and 79.3 million in 2025, respectively. The trend of global type 2 diabetes burden was similar to that of total diabetes (including type 1 diabetes and type 2 diabetes), while global age-standardized rate of mortality and DALYs for type 1 diabetes declined. Globally, metabolic risks (high BMI) and behavioral factors (inappropriate diet, smoking, and low physical activity) contributed the most attributable death and DALYs of diabetes. These estimations could be useful in policy-making, priority setting, and resource allocation in diabetes prevention and treatment.
                Bookmark

                Author and article information

                Contributors
                martina.kropp@unige.ch
                olga.golubnitschaja@ukbonn.de
                Journal
                EPMA J
                EPMA J
                The EPMA Journal
                Springer International Publishing (Cham )
                1878-5077
                1878-5085
                13 February 2023
                13 February 2023
                March 2023
                : 14
                : 1
                : 21-42
                Affiliations
                [1 ]GRID grid.150338.c, ISNI 0000 0001 0721 9812, Division of Experimental Ophthalmology, Department of Clinical Neurosciences, , University of Geneva University Hospitals, ; 1205 Geneva, Switzerland
                [2 ]GRID grid.150338.c, ISNI 0000 0001 0721 9812, Ophthalmology Department, , University Hospitals of Geneva, ; 1205 Geneva, Switzerland
                [3 ]GRID grid.15090.3d, ISNI 0000 0000 8786 803X, Predictive, Preventive and Personalised (3P) Medicine, Department of Radiation Oncology, , University Hospital Bonn, Rheinische Friedrich-Wilhelms-Universität Bonn, ; 53127 Bonn, Germany
                [4 ]GRID grid.7634.6, ISNI 0000000109409708, Clinic of Obstetrics and Gynecology, Jessenius Faculty of Medicine, , Comenius University in Bratislava, ; 036 01 Martin, Slovakia
                [5 ]GRID grid.419498.9, ISNI 0000 0001 0660 6765, Max Planck Institute for Plant Breeding Research, ; Carl-Von-Linne-Weg 10, 50829 Cologne, Germany
                [6 ]GRID grid.4491.8, ISNI 0000 0004 1937 116X, Department of Histology and Embryology, and Biomedical Centre, Faculty of Medicine in Plzen, , Charles University, ; Prague, Czech Republic
                [7 ]GRID grid.4491.8, ISNI 0000 0004 1937 116X, Department of Neurology, University Hospital Plzen, and Faculty of Medicine in Plzen, , Charles University, ; 100 34 Prague, Czech Republic
                [8 ]GRID grid.4491.8, ISNI 0000 0004 1937 116X, Department of Neurology, University Hospital Kralovske Vinohrady, Third Faculty of Medicine, , Charles University, ; Prague, Czech Republic
                [9 ]GRID grid.7634.6, ISNI 0000000109409708, Department of Medical Biology, Jessenius Faculty of Medicine, , Comenius University in Bratislava, ; 036 01 Martin, Slovakia
                Author information
                http://orcid.org/0000-0001-5427-2018
                Article
                314
                10.1007/s13167-023-00314-8
                9971534
                36866156
                a3afb8a2-9928-46e5-91f1-1d2626e0f19e
                © The Author(s) 2023

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 11 January 2023
                : 15 January 2023
                Funding
                Funded by: Rheinische Friedrich-Wilhelms-Universität Bonn (1040)
                Categories
                Review
                Custom metadata
                © The Author(s), under exclusive licence to European Association for Predictive, Preventive and Personalised Medicine (EPMA) 2023

                Molecular medicine
                predictive, preventive, and personalised medicine (3p/pppm),diabetes mellitus,comorbidities,diabetic complications,retinopathy,proliferative diabetic retinopathy,blindness,global burden,health-to-disease transition,primary and secondary prevention,domino effect,cerebral small vessel disease,stress,ros,ischemic stroke,mitochondrial injury,cell death,metabolic and signalling shifts,inflammation,neovascularisation,analytical tools,tear fluid,molecular patterns,biomarkers,health policy

                Comments

                Comment on this article